Skip to main content
letter
. 2020 Mar 23;75(8):10.1111/all.14266. doi: 10.1111/all.14266

Figure 1.

Figure 1

Ratio of the annual rate of clinically significant exacerbations with mepolizumab 100 mg SC versus placebo by baseline biomarker and PBEC subgroup. CI, confidence interval; ECP, eosinophil cationic protein; EDN, eosinophil‐derived neurotoxin; PBEC, peripheral blood eosinophil count; SC, subcutaneous